A Phase I, Single Center, Open-Label, Randomized, Single Dose Cross-Over Study in Healthy Male Subjects to Investigate the Bioequivalence and Tolerability of Liquid and Reconstituted Lyophilized Subcutaneous Formulations of Caplacizumab.
Phase of Trial: Phase I
Latest Information Update: 17 Nov 2014
Price : $35 *
At a glance
- Drugs Caplacizumab (Primary) ; Caplacizumab
- Indications Thrombotic thrombocytopenic purpura
- Focus Pharmacokinetics
- Sponsors Ablynx
- 13 Nov 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 17 Jul 2014 New trial record